Skip to main content

DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

The recorded presentation will be available on the Investors section of the Company’s website at https://www.diamedica.com/investors/events-presentations beginning Thursday, April 29th.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, visit www.diamedica.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  212.79
+3.02 (1.44%)
AAPL  258.86
+2.94 (1.15%)
AMD  220.18
+2.68 (1.23%)
BAC  50.06
+0.68 (1.38%)
GOOG  297.66
+3.20 (1.09%)
META  573.02
-1.44 (-0.25%)
MSFT  372.88
-0.58 (-0.16%)
NVDA  177.64
+0.25 (0.14%)
ORCL  145.54
-0.84 (-0.57%)
TSLA  352.82
-7.77 (-2.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.